drugset / Trial / NCT05769010
Study of SHR-A1811 in HER2-expression Advanced Breast Cancer With Brain Metastases
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study aimed to evaluate the use of SHR-A1811 in HER2-expression Advanced Breast Cancer patients with brain metastases.
Timeline
- Start
- 2023-03-31
- Primary completion
- 2028-12-30
- Completion
- 2029-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Adebelizumab | Unknown | — | Intravenous |
| Subject | Bevacizumab | Monoclonal antibody | — | Intravenous |
| Subject | Pyrotinib | Small molecule | — | Oral |
| Subject | Trastuzumab Rezetecan | Monoclonal antibody | — | Intravenous |